<ul>
<li>5 只医疗股票的收益增长达到三位数</li>
</ul>
<p>Axsome Therapeutics, Inc. (NASDAQ:AXSM - 免费报告) - Zacks Research 在 2023 年 4 月 7 日周一向投资者发布的报告中下调了对 Axsome Therapeutics 2027 年第一季度每股收益的预期。Zacks Research 分析师 R. Department 现在预计该公司本季度每股收益为 0.75 美元，低于之前的 0.92 美元预期。Axsome Therapeutics 当前全年的共识预期为每股（-2.79 美元）。Zacks Research 还对 Axsome Therapeutics 2027 财年的每股收益预期为 5.37 美元。</p>
<p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
<p>其他几位股票研究分析师最近也对 AXSM 发表了评论。美国银行在 2023 年 2 月 11 日的研究报告中将 Axsome Therapeutics 的目标价从 143.00 美元上调至 167.00 美元，并给予该股票 “买入” 评级。加拿大皇家银行在 2023 年 2 月 19 日的研究报告中将 Axsome Therapeutics 的目标价从 143.00 美元上调至 192.00 美元，并给予该公司 “跑赢大盘” 评级。Needham &amp; Company LLC 在 2023 年 4 月 1 日的报告中重新发布了 “买入” 评级，并对 Axsome Therapeutics 的股票设定了 153.00 美元的目标价。Robert W. Baird 在 2023 年 3 月 3 日的报告中将 Axsome Therapeutics 的目标价从 132.00 美元上调至 160.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Leerink Partners 在 2023 年 2 月 10 日的报告中将 Axsome Therapeutics 的目标价从 110.00 美元上调至 150.00 美元，并给予该股票 “跑赢大盘” 评级。一位股票研究分析师对该股票给予了持有评级，十六位分析师给予了买入评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 169.80 美元。</p>
<ul>
<li>处于困境的 Axsome 股票可能因药物试验成功而反弹</li>
</ul>
<p><strong>获取我们关于 Axsome Therapeutics 的最新报告</strong></p>
<h2>Axsome Therapeutics 股票表现</h2>
<p>Axsome Therapeutics 的股票在周二以 98.50 美元开盘。该公司的市值为 48 亿美元，市盈率为-16.44，贝塔值为 0.88。Axsome Therapeutics 的 52 周低点为 64.11 美元，52 周高点为 139.13 美元。该公司的速动比率为 2.04，流动比率为 2.11，债务与股本比率为 3.22。该公司的 50 日移动平均价格为 120.54 美元，200 日移动平均价格为 101.85 美元。</p>
<ul>
<li>为什么现在是购买 Axsome Therapeutics 的绝佳时机</li>
</ul>
<p>Axsome Therapeutics (NASDAQ:AXSM - 获取免费报告) 最后一次公布财报是在 2023 年 2 月 18 日。该公司报告本季度每股收益为（-0.96 美元），超出市场共识预期的（-0.97 美元）0.01 美元。Axsome Therapeutics 的股本回报率为-223.51%，净利润率为-74.47%。该公司本季度的收入为 1.1877 亿美元，而分析师预期为 1.1783 亿美元。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席财务官 Nick Pizzie 在 2023 年 2 月 14 日的交易中出售了 3,000 股公司的股票。股票以 131.07 美元的平均价格出售，总价值为 393,210.00 美元。交易完成后，首席财务官现在直接持有公司 42,187 股股票，价值为 5,529,450.09 美元。此次交易使其持股减少了 6.64%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接获取。内部人士持有公司 22.40% 的股份。</p>
<h2>机构资金流入和流出</h2>
<p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。BVF Inc. IL 在第四季度将其在 Axsome Therapeutics 的持股增加了 32.7%。BVF Inc. IL 现在拥有 1,388,064 股公司股票，价值为 1.17444 亿美元，此前在上个季度购买了 342,064 股。Geode Capital Management LLC 在第四季度将其在 Axsome Therapeutics 的持仓增加了 0.4%。Geode Capital Management LLC 现在拥有 912,538 股公司股票，价值为 77228000 美元，此前在上个季度购买了 4,079 股。Wellington Management Group LLP 在第三季度将其在 Axsome Therapeutics 的持股增加了 1.1%。Wellington Management Group LLP 现在拥有 742,745 股公司股票，价值为 66750000 美元，此前在上个季度购买了 8,125 股。Invesco Ltd.在第四季度将其在 Axsome Therapeutics 的持股增加了 10.8%。Invesco Ltd.现在拥有 692,464 股公司股票，价值为 58589000 美元，此前在上个季度购买了 67,285 股。最后，Hood River Capital Management LLC 在第四季度将其在 Axsome Therapeutics 的持股增加了 3.2%。Hood River Capital Management LLC 现在拥有 644,785 股公司股票，价值为 54555000 美元，此前在上个季度购买了 19,701 股。对冲基金和其他机构投资者持有公司 81.49% 的股份。</p>
<h2>Axsome Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Axsome Therapeutics, Inc.是一家生物制药公司，专注于在美国开发针对中枢神经系统（CNS）疾病的新疗法。该公司的商业产品组合包括 Auvelity（右美沙芬 - 布普洛尼），这是一种具有多重作用的 N-甲基-D-天冬氨酸受体拮抗剂，适用于治疗重度抑郁症；以及 Sunosi（索利美特），这是一种用于治疗嗜睡症或阻塞性睡眠呼吸暂停患者的白天过度嗜睡的药物。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Axsome Therapeutics</li>
<li>如何投资 FAANG 股票</li>
<li>期权活动指向 Palantir 股票将出现更多波动</li>
<li>投资便士股票需要了解的事项</li>
<li>NVIDIA 股票：被低估，价值被忽视——它还能跌到多低？</li>
<li>最佳股票，价格低于 5.00 美元</li>
<li>MicroStrategy 在第一季度看到内部买卖活动</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
<p>在考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Axsome Therapeutics 并不在名单上。</p>
<p>虽然 Axsome Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AXSM

<p>Zacks Research 对 Axsome Therapeutics (NASDAQ:AXSM) 发布了负面展望，将其 2027 年第一季度每股收益预期从 0.92 美元下调至 0.75 美元。全年收益的共识预期为每股 -2.79 美元。尽管如此，几位分析师已上调了该股票的目标价，整体评级为 “适度买入”，平均目标价为 169.80 美元。Axsome 的股票开盘价为 98.50 美元，市值为 48 亿美元，市盈率为 -16.44</p>

<ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只医疗股票的收益增长达到三位数</li>
</ul>
</div><p>Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Zacks Research reduced their Q1 2027 EPS estimates for Axsome Therapeutics in a note issued to investors on Monday, April 7th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.75 per share for the quarter, down from their previous estimate of $0.92. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics' FY2027 earnings at $5.37 EPS.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc. (NASDAQ:AXSM - 免费报告) - Zacks Research 在 2023 年 4 月 7 日周一向投资者发布的报告中下调了对 Axsome Therapeutics 2027 年第一季度每股收益的预期。Zacks Research 分析师 R. Department 现在预计该公司本季度每股收益为 0.75 美元，低于之前的 0.92 美元预期。Axsome Therapeutics 当前全年的共识预期为每股（-2.79 美元）。Zacks Research 还对 Axsome Therapeutics 2027 财年的每股收益预期为 5.37 美元。</p>
</div><p>Get <strong>Axsome Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
</div><p>Several other equities research analysts also recently commented on AXSM. Bank of America lifted their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, February 11th. Royal Bank of Canada boosted their price target on Axsome Therapeutics from $143.00 to $192.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, February 19th. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, April 1st. Robert W. Baird lifted their target price on Axsome Therapeutics from $132.00 to $160.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday, March 3rd. Finally, Leerink Partners increased their price target on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $169.80.</p>
<div class="lb-trans"><p>其他几位股票研究分析师最近也对 AXSM 发表了评论。美国银行在 2023 年 2 月 11 日的研究报告中将 Axsome Therapeutics 的目标价从 143.00 美元上调至 167.00 美元，并给予该股票 “买入” 评级。加拿大皇家银行在 2023 年 2 月 19 日的研究报告中将 Axsome Therapeutics 的目标价从 143.00 美元上调至 192.00 美元，并给予该公司 “跑赢大盘” 评级。Needham &amp; Company LLC 在 2023 年 4 月 1 日的报告中重新发布了 “买入” 评级，并对 Axsome Therapeutics 的股票设定了 153.00 美元的目标价。Robert W. Baird 在 2023 年 3 月 3 日的报告中将 Axsome Therapeutics 的目标价从 132.00 美元上调至 160.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Leerink Partners 在 2023 年 2 月 10 日的报告中将 Axsome Therapeutics 的目标价从 110.00 美元上调至 150.00 美元，并给予该股票 “跑赢大盘” 评级。一位股票研究分析师对该股票给予了持有评级，十六位分析师给予了买入评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 169.80 美元。</p>
</div><ul>
<li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li>
</ul>
<div class="lb-trans"><ul>
<li>处于困境的 Axsome 股票可能因药物试验成功而反弹</li>
</ul>
</div><p><strong>Get Our Latest Report on Axsome Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Axsome Therapeutics 的最新报告</strong></p>
</div><h2>Axsome Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 股票表现</h2>
</div><p>Shares of Axsome Therapeutics stock opened at $98.50 on Tuesday. The firm has a market capitalization of $4.80 billion, a P/E ratio of -16.44 and a beta of 0.88. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The company has a 50 day moving average price of $120.54 and a 200 day moving average price of $101.85.</p>
<div class="lb-trans"><p>Axsome Therapeutics 的股票在周二以 98.50 美元开盘。该公司的市值为 48 亿美元，市盈率为-16.44，贝塔值为 0.88。Axsome Therapeutics 的 52 周低点为 64.11 美元，52 周高点为 139.13 美元。该公司的速动比率为 2.04，流动比率为 2.11，债务与股本比率为 3.22。该公司的 50 日移动平均价格为 120.54 美元，200 日移动平均价格为 101.85 美元。</p>
</div><ul>
<li>Why this is an Awesome Time to Buy Axsome Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么现在是购买 Axsome Therapeutics 的绝佳时机</li>
</ul>
</div><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The company had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million.</p>
<div class="lb-trans"><p>Axsome Therapeutics (NASDAQ:AXSM - 获取免费报告) 最后一次公布财报是在 2023 年 2 月 18 日。该公司报告本季度每股收益为（-0.96 美元），超出市场共识预期的（-0.97 美元）0.01 美元。Axsome Therapeutics 的股本回报率为-223.51%，净利润率为-74.47%。该公司本季度的收入为 1.1877 亿美元，而分析师预期为 1.1783 亿美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Insiders own 22.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席财务官 Nick Pizzie 在 2023 年 2 月 14 日的交易中出售了 3,000 股公司的股票。股票以 131.07 美元的平均价格出售，总价值为 393,210.00 美元。交易完成后，首席财务官现在直接持有公司 42,187 股股票，价值为 5,529,450.09 美元。此次交易使其持股减少了 6.64%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接获取。内部人士持有公司 22.40% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. BVF Inc. IL lifted its holdings in Axsome Therapeutics by 32.7% during the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock valued at $117,444,000 after purchasing an additional 342,064 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Axsome Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 912,538 shares of the company's stock worth $77,228,000 after purchasing an additional 4,079 shares during the last quarter. Wellington Management Group LLP lifted its stake in Axsome Therapeutics by 1.1% in the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company's stock valued at $66,750,000 after buying an additional 8,125 shares in the last quarter. Invesco Ltd. boosted its holdings in Axsome Therapeutics by 10.8% in the 4th quarter. Invesco Ltd. now owns 692,464 shares of the company's stock worth $58,589,000 after buying an additional 67,285 shares during the last quarter. Finally, Hood River Capital Management LLC increased its stake in Axsome Therapeutics by 3.2% during the 4th quarter. Hood River Capital Management LLC now owns 644,785 shares of the company's stock worth $54,555,000 after buying an additional 19,701 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。BVF Inc. IL 在第四季度将其在 Axsome Therapeutics 的持股增加了 32.7%。BVF Inc. IL 现在拥有 1,388,064 股公司股票，价值为 1.17444 亿美元，此前在上个季度购买了 342,064 股。Geode Capital Management LLC 在第四季度将其在 Axsome Therapeutics 的持仓增加了 0.4%。Geode Capital Management LLC 现在拥有 912,538 股公司股票，价值为 77228000 美元，此前在上个季度购买了 4,079 股。Wellington Management Group LLP 在第三季度将其在 Axsome Therapeutics 的持股增加了 1.1%。Wellington Management Group LLP 现在拥有 742,745 股公司股票，价值为 66750000 美元，此前在上个季度购买了 8,125 股。Invesco Ltd.在第四季度将其在 Axsome Therapeutics 的持股增加了 10.8%。Invesco Ltd.现在拥有 692,464 股公司股票，价值为 58589000 美元，此前在上个季度购买了 67,285 股。最后，Hood River Capital Management LLC 在第四季度将其在 Axsome Therapeutics 的持股增加了 3.2%。Hood River Capital Management LLC 现在拥有 644,785 股公司股票，价值为 54555000 美元，此前在上个季度购买了 19,701 股。对冲基金和其他机构投资者持有公司 81.49% 的股份。</p>
</div><h2>Axsome Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc.是一家生物制药公司，专注于在美国开发针对中枢神经系统（CNS）疾病的新疗法。该公司的商业产品组合包括 Auvelity（右美沙芬 - 布普洛尼），这是一种具有多重作用的 N-甲基-D-天冬氨酸受体拮抗剂，适用于治疗重度抑郁症；以及 Sunosi（索利美特），这是一种用于治疗嗜睡症或阻塞性睡眠呼吸暂停患者的白天过度嗜睡的药物。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Axsome Therapeutics</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Options Activity Points to More Volatility for Palantir Stock</li>
<li>What to Know About Investing in Penny Stocks</li>
<li>NVIDIA Stock: Oversold, Undervalued — How Low Can It Go?</li>
<li>Best Stocks Under $5.00</li>
<li>MicroStrategy Sees Insider Buy-Sell Action in Q1</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Axsome Therapeutics</li>
<li>如何投资 FAANG 股票</li>
<li>期权活动指向 Palantir 股票将出现更多波动</li>
<li>投资便士股票需要了解的事项</li>
<li>NVIDIA 股票：被低估，价值被忽视——它还能跌到多低？</li>
<li>最佳股票，价格低于 5.00 美元</li>
<li>MicroStrategy 在第一季度看到内部买卖活动</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=AXSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
</div><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Axsome Therapeutics 并不在名单上。</p>
</div><p>While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Axsome Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Zacks 研究对 Axsome Therap 的收益发布负面展望